A short list can leave large gaps.

Check off the idea

Understand FDA’s concern

• Ask how the product would be given

  FDA’s entry, checked September 30, 2026, warns about clumps of Selank or unwanted material mixed with it. These could make the body’s defence system treat Selank as an invader.

  FDA says this concern depends on how Selank is given, but the entry does not name those ways.

• Keep the wording precise

  This warning describes a possible risk. It does not show that any particular product contains unwanted material.

• Name what is still unknown

  Ask whether the proposed product is a shot, drops for the nose, or something else. Ask what is known about that exact product.

A note to keep

Read the leaflet as a limited source

The Russian maker’s leaflet mentions unpleasant taste and possible allergic reactions.

It gives no rate for those effects, and its short list cannot establish safety.

The leaflet rules out use during pregnancy or breastfeeding and in people younger than 18; those groups were not studied.

At the September 30, 2026 check, Selank had no official U.S. medicine information reviewed by FDA. There was no FDA-reviewed guide to the checks, tests, or follow-up needed when using it.

Check off the idea

Bring the other medicines into the conversation

• Bring the whole list

  Include medicines for mood, sleep, or anxiety, plus anything else you take.

• Ask what the evidence leaves out

  Lab and rat studies suggest that Selank can change the effects of some calming medicines. What happens when people take them together has not been studied.

  These findings cannot tell you whether Selank would make your medicine stronger or weaker, or what harm could result.

• Ask about the conflicting claims

  The Russian maker’s leaflet says Selank can be taken with any medicine acting on the brain or nerves. Lab studies suggest it can change how some of those medicines act, so the leaflet does not settle the question.